Heterologous priming-boosting vaccination regimens involving priming with plasmid DNA antigen constructs and inoculating (boosting) with the same recombinant antigen expressed in replication-attenuated poxviruses have recently been demonstrated to induce immunity, based on CD4 ؉ -and CD8 ؉ -T-cell responses, against several diseases in both rodents and primates. We show that similar priming-boosting vaccination strategies using the 85A antigen of Mycobacterium tuberculosis are effective in inducing antigen-specific gamma interferon-secreting CD4
Infections with Mycobacterium bovis in cattle and wildlife hosts constitute a major economic burden worldwide in terms of loss of production and the cost of disease surveillance (9) . Infected cattle often suffer clinical disease, bovine tuberculosis, and pose a considerable public health risk, especially in certain communities in developing countries that consume raw milk, where the incidence of this disease is increasing with the advent of pandemic human immunodeficiency virus (HIV)-induced syndrome (14) . Control of M. bovis infections by the test-and-slaughter strategy is largely effective but not widely applied because of its uneconomical nature. Although initial experimental studies in which cattle were vaccinated with M. bovis bacillus Calmette-Guérin (BCG) demonstrated modest efficacy levels (36) , subsequent trials have provided evidence for protection against clinical disease (8) . However, the adoption of this vaccination regimen as a control measure for bovine tuberculosis has hitherto been complicated by the difficulty associated with differentiating between vaccinated and infected cattle (9, 34) . This complication has been addressed in more recent studies indicating the potential of defined antigens to distinguish between these two groups of exposed cattle (34, 35) . Studies with BCG in humans and animals have, however, been useful in providing insights into the mechanisms of protection against tuberculosis, which is crucial to the rational design of new improved tuberculosis vaccines (8, 19, 27, 30) .
Intense efforts are, therefore, currently focused on developing subunit vaccines capable of inducing robust immunity based on antigen-specific CD4 ϩ -and CD8 ϩ -T-cell responses. Initial attempts to immunize cattle with recombinant protein or plasmid DNA failed to induce appropriate immune responses (9) , which highlights the need to evaluate vaccination regimens that have been shown, in other systems, to induce strong cell-mediated immune responses. Studies using animal models of malaria, tuberculosis, and HIV infection have shown that the immunogenicity of plasmid DNA, influenza virus, or adenovirus in priming T-cell responses to defined antigens can be markedly enhanced by inoculating (boosting) with the modified vaccinia virus Ankara strain (MVA) or fowlpox virus (FP9) expressing the same antigens (1, 7, 12, 17, 21, 24, 28, 29) . These experiments also demonstrated that the efficacy of protection to lethal challenge was enhanced upon boosting, and in some cases sterile immunity was achieved (7, 28) .
A number of mycobacterial antigens have been studied in murine models and in BCG-vaccinated humans for their potential as targets for T-cell immunity. Secreted extracellular antigens have been found to be prime candidates. The antigen 85 complex, which comprises three distinct but highly conserved proteins (85A, -B, and -C), constitutes 30% of the M. tuberculosis and M. bovis BCG culture filtrate proteins (37). 85A represents a major portion of the complex and has been shown to be a key antigenic target for CD4 ϩ -and CD8 ϩ -T-cell responses in BCG-vaccinated donors (20, 26, 30, 31) . Immunization of mice using 85A plasmid DNA has resulted in significant induction of CD4 ϩ -and CD8 ϩ -T-cell responses but only partial immunity to challenge (11, 15, 22) . Further studies of mice have demonstrated enhancement of T-cell immunogenicity and improved protection to challenge following 85A plasmid DNA priming and protein boosting (32) .
The present study seeks to evaluate the utility of a strategy involving priming with plasmid DNA or recombinant FP9 and boosting with recombinant MVA expressing 85A to induce antigen-specific T-cell responses in cattle as a basis for developing a subunit vaccine against bovine tuberculosis. Priming with either of the two agents and boosting with recombinant MVA elicited significant frequencies of peptide-specific gamma interferon (IFN-␥)-secreting T cells in immunized cattle. In general, IFN-␥-secreting T cells were capable of proliferating upon further peptide stimulation. These findings raise the prospect of assessing this vaccination regimen in cattle challenged with virulent M. bovis.
PFU of FP-85A given intradermally (i.d.). First and second booster immunizations with 10 9 PFU of MVA-85A were administered i.d. at weeks 4 and 8, respectively.
Marsupialization of the spleen. In order to gain easy access to the spleen for repetitive biopsies, the spleens of cattle in group 1 were "marsupialized." Briefly, the animals were put under general anesthesia and a laparotomy was performed on the left side via the 12th rib. The tail of the spleen was secured in a pouch between the skin and the intercostal muscle anterior to the 13th rib. By introducing a 16-guage needle through the overlying skin and into the spleen, samples of spleen could be aspirated with a syringe containing Alsever's solution. As the tail of the spleen was held snugly in the pouch, postaspiration hemorrhage was minimal.
Preparation of splenocytes and PBMC. Isolation of peripheral blood mononuclear cells (PBMC) from the venous blood-Alsever's solution mixture and splenocytes teased from spleen needle biopsy specimens was achieved by flotation on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) as described before (13) . Cells were counted before cell depletions were conducted.
Cell depletions. Splenocytes and PBMC were depleted of T cells bearing the ␥␦ antigen receptor and B lymphocytes (hereinafter referred to as d-SPL and d-PBL, respectively) before use in in vitro assays. In certain instances, CD4 ϩ or CD8 ϩ T cells plus monocytes were purified and used in assays. Cell purifications were achieved by negative selection. Undesirable cell subpopulations were stained with specific monoclonal antibodies, and anti-mouse immunoglobulin G antibody-conjugated ferrous beads (Dynal, Oslo, Norway) were added. The cellbead mixture was put in a magnet, and unbound cells were collected.
Peptides. Overlapping peptides spanning the entire length of the 85A protein of M. tuberculosis were purchased from Research Genetics (Huntsville, Ala.). The peptides were 20 residues long and overlapped by 10 amino acids as shown in Table 3 . Peptide synthesis was confirmed by high-performance liquid chromatography and mass spectrometry profiles to be on the order of Ͼ80% purity.
Quantification of peptide-specific T cells by the ELISPOT assay. The frequency of peptide-specific IFN-␥-releasing T cells in immunized cattle was determined using a direct ex vivo enzyme-linked immunospot (ELISPOT) assay essentially as described before (25, 31) with modifications. Briefly, 96-well polyvinylidene difluoride-backed plates (MAIP S45; Millipore) were precoated with anti-bovine IFN-␥ capture monoclonal antibody 2-2-1 (5 g/ml; Serotec) overnight at 4°C. Plates were washed twice with Optimem (Gibco BRL, Paisley, United Kingdom)-2% (vol/vol) heat-inactivated fetal calf serum (FCS) (Life Technologies Ltd., Paisley, United Kingdom) and blocked with Optimem-10% FCS for 2 h at 37°C. Peptides at a final concentration of 10 g/ml in Optimem-2% FCS were added in 50-l aliquots to the wells. A control well with medium alone and another well with concanavalin A (Sigma Chemical Co.) at a final concentration of 5 g/ml were included. Responder cells (d-SPL, d-PBL, CD4 ϩ , or CD8 ϩ T cells) were added in 50-l aliquots containing 2.5 ϫ 10 5 cells per well. A precoated well with no cells added was also included. Plates were kept for 20 h in a humidified incubator at 37°C and 5% CO 2 . After the cells were shaken off, the plates were washed twice with distilled water and then thrice with PBS 0.05%-Tween 20 (Sigma Chemical Co.), each time with a plate being shaken on a shaker for 20 s before the wash fluid was flicked off. A second rabbit anti-bovine IFN-␥ antibody (an in-house reagent used at 1:1,500) was added in 100-l aliquots, and the plates were incubated for 1 h at room temperature. A further three washes with PBS-Tween 20 were performed without shaking the plates before addition of an anti-rabbit immunoglobulin G-alkaline phosphatase conjugate (clone R696 [100 l/well; 1:2,000 in PBS-T-bovine serum albumin]; Sigma Chemical Co.) for 1 h at room temperature. Plates were further washed six times before 100 l of chromogenic alkaline phosphatase substrate (5-bromo-4-chloro-3-indolylphosphate-nitroblue tetrazolium; Sigma Chemical Co.) was added to each well for up to 5 min in the dark to allow spot development. Copious amounts of tap water were added, and the plates were air dried. Spots were initially observed under a dissection microscope (Ernst Leitz Wetzlar GmbH, Germany) and then counted using an ELISPOT Reader (Autoimmun Diagnostika GmbH, Strassberg, Germany). Statistical analysis. Individual ELISPOT values were transformed to logarithms. These were then analyzed using a repeated-measures analysis of variance by immunization group. The means on the logarithmic scale were then detransformed to derive geometric means.
RESULTS
Priming with 85A plasmid DNA and boosting with recombinant MVA elicits peptide-specific IFN-␥-secreting T cells. To assess whether priming with pSG2-85A and boosting with MVA-85A induces 85A-specific IFN-␥-producing T cells in cattle, two animals (BT37 and BT99) were inoculated with recombinant plasmid DNA and recombinant MVA, and another two cattle (BT47 and BT53) were inoculated with empty plasmid DNA and wild-type MVA as shown in Table 1 . ELISPOT assays were performed with d-SPL obtained prior to vaccination; 14 days after DNA immunization; 7, 14, and 21 days and 6 months after the first MVA booster injection; and 7, 14, and 32 days and 16 weeks after the second MVA booster and at 10 days after the third MVA booster. Due to the initial problems of high background in the assays, cells taken before vaccination; 14 days after DNA inoculation; and at 7, 14, and 21 days after the first MVA booster were cryopreserved during further assay optimization. For assays performed at the other time points, freshly isolated cells were utilized without cryopreservation.
As shown in Fig. 1 , peptide-specific T cells detectable in all the animals prior to immunization were at marginal levels (Ͻ5 to 15 spot-forming cells (SFC) per 10 6 cells), and these frequencies were similar to those observed at 14 days after DNA inoculation. By contrast, at days 7, 14, and 21 (cells at these three time points were pooled to obtain sufficient numbers) following the first MVA booster, the frequencies of peptidespecific T cells from 85A-immunized animals increased nearly fivefold to 70 to 90 SFC per 10 6 cells, while those observed with cells from control animals were either unaltered or showed a slight increase above marginal levels. When tested next at 6 months, peptide-specific cytokine responses in all the animals were either undetectable or marginal. Further assays conducted at days 7, 14, and 32 following a second virus booster revealed levels as high as 220 to 260 SFC/10 6 cells in the test animals, compared with 10 to 50 SFC/10 6 cells observed in the control group. However, at 16 weeks after the second virus booster, frequencies of peptide-specific T cells detected in the test animals had declined approximately 8-to 10-fold (corresponding assays were not performed with the control group). The test animals received further boosters with recombinant MVA, and assays performed at 10 days showed a steep rise (190 to 230 SFC/10 6 cells) in the frequencies of peptide-specific cells.
Collectively, these data indicate that the induction of peptide-specific T cells in the animals is a consequence of immunization with 85A-expressing plasmid DNA and boosting with recombinant MVA and that priming with 85A DNA is insufficient, on its own, to induce detectable responses. The data also demonstrate that detectable responses last for periods less than 6 months but that the animals can again be vaccinated with the booster to obtain high-level responses, suggesting that memory T cells are maintained in vivo despite the inability to detect them in vitro.
Comparison of peptide-specific responses in spleen and peripheral blood. Splenocytes and PBMC were prepared from Table 2 . d-PBL were prepared from the animals prior to immunization, 14 days after each DNA prime, 7 and 21 days after the first MVA booster, and 14 days after the second MVA booster and were subjected to ELISPOT assays. As shown in Fig. 3A , frequencies ranging from Ͻ5 to 24 SFC/10 6 cells were observed prior to immunization and after the first DNA prime, and these responses showed a general, albeit slight, increase to 15 to 36 SFC/10 6 cells following the second DNA prime. Assays performed 7 and 14 days after the first MVA booster showed either a slight or no increase (10 to 66 SFC/10 6 cells) in the frequencies of responding cells from 3 animals (BV159, BV162 and BV165), and a markedly enhanced response (275 to 287 SFC/10 6 cells) in 1 animal (BV156). Similar levels of responses were observed at 14 days after the second MVA booster.
The data from these two groups of cattle (experiment 2), compared to those from experiment 1, indicate that an in- Recombinant FP9 priming generates moderate but clearly detectable responses that are boosted significantly by recombinant MVA. To evaluate the utility of priming with recombinant FP and boosting with MVA expressing 85A to induce antigen-specific T cells, four cattle were immunized as described in experiment 3 above, and ELISPOT assays were conducted at different time points. As shown in Fig. 4 Together, the data indicate that FP priming induced responses detectable above the preimmunization levels, although considerable variation between animals was exhibited. The other major observation is the general boosting effect by recombinant MVA seen in all the animals. The geometric mean, 205 SFC/10 6 cells (range, 46 to 815 SFC/10 6 cells), of responses after the MVA booster is similar to that for the group subjected to DNA priming i.d. but higher than that for the group subjected to DNA priming i.m. (P ϭ 0.09).
T-cell reactivity to individual peptides was disparate in the majority of animals. Responses to all regions of 85A were detected in different animals, as shown in Fig. 5 , indicating that there appears to be no obvious immunodominant portion of the molecule. Responses to some peptides were detected only after a second booster, exhibiting the phenomenon of "epitope spreading" as described previously (33) .
The frequency of peptide-specific IFN-␥-secreting CD4 ؉ T cells induced was higher than that of CD8 ؉ T cells irrespective of the immunization regimen. Assays were carried out utilizing purified CD4 ϩ or CD8 ϩ T cells in the presence of monocytes and 85A peptides to determine T-cell-subset-restricted responses. Cells from the four groups of cattle reflecting four different immunization regimens were included in the assays. Results of these experiments are shown in Fig. 6 . Frequencies of peptide-specific CD8 ϩ T cells ranged between 91 and 1,465 SFC/10 6 cells, while those of CD4 ϩ T cells ranged from 349 to 3,292 SFC/10 6 cells. Except for animal BV156, in which the CD4/CD8 T-cell responding ratio was 1:1, all the other animals exhibited a CD8
ϩ -T-cell response that was 10 to 50% that of the CD4 ϩ T cells. It is evident from these findings that the majority of animals generated a predominantly CD4 ϩ -biased T-cell peptide-specific response regardless of the immunization protocol.
Peptide-specific IFN-␥-secreting T cells are capable of undergoing proliferation in response to further stimulation. Experiments were carried out to determine whether T cells that produced IFN-␥ in response to 85A peptides were capable of peptide-specific lymphoproliferation. Cultures of d-PBL were incubated in the presence of 85A peptides as described in Materials and Methods. Cultures to which no peptide or irrelevant peptides derived from a Theileria parva polymorphic immunodominant molecule were added served as controls. (Fig. 3) , it is evident that animals that exhibited an IFN-␥ response were capable of mounting a peptide-specific T-cell proliferative activity.
T-cell reactivity to PPD of M. bovis and M. avium. As described in Materials and Methods, d-SPL and d-PBL were evaluated for their capacity to proliferate to PPD derived from M. bovis and M. avium prior to and periodically after immunization. Marginal or no reactivity to PPD was demonstrated (data not shown).
DISCUSSION
An effective vaccine against M. bovis infection in cattle is needed in both developed and developing countries. In the United Kingdom an expensive and extensive test-and-slaughter policy has failed to prevent a sharp increase in cases of bovine tuberculosis, and a recent scientific review has concluded that the best prospect for long-term control of the disease is the development of a vaccine (18) . In African countries, such as Tanzania, milk is not normally pasteurized, and in specific foci within pastoralist agro-ecosystems, M. bovis can be present in milk for human consumption, representing a serious public health risk in a country where the rate of HIV is increasing (16) . One promising option for control of M. bovis infection in such a setting is an inexpensive, safe, and effective vaccine capable of generating long-term immunity. Vaccination with the BCG attenuated live vaccine can often be ineffective due to prior exposure of livestock or humans to related strains of M. bovis (6) . A similar problem should not apply to subunit vaccines based on priming and boosting with defined recombinant antigens.
Heterologous priming-boosting immunization has been used to generate antigen-specific T-cell responses in several animal models of human diseases, and clinical trials are now in progress for immunization against malaria, HIV, tuberculosis, and melanoma using different versions of this technology, but in particular using a recombinant attenuated poxvirus to boost a previously primed response to the same antigen. We report here the application of this technology to cattle to immunize against an economically important cattle disease. Immunization with 85A in both DNA-MVA and FP9-MVA priming-boosting regimens induced high levels of T-cell responses in the majority of immunized animals. Responses could be detected in T cells obtained from both spleen and blood. No response to PPD from either M. bovis or M. avium was detected, indicating that the cattle had not previously been exposed to these microorganisms. Responses were very low or undetectable following DNA immunization whether administered i.m. or i.d., despite using a high dose (4 mg). Allowing for the small sample size, the results suggest that the route of DNA administration had an effect on the responses obtained after MVA boosting; higher responses were obtained after i. Further comparison of the two regimens will be necessary to decide which is the more immunogenic. For practical purposes, the FP9-MVA regimen has an advantage over that with DNA-MVA since the manufacturing processes for both FP9-and MVA-based vaccines are very similar. Production of both vaccines is straightforward, and production plants could be set up in the developing countries where the vaccine is needed, thereby reducing the production costs. Manufacture of DNA vaccines requires a different process and more-specialized reagents and is therefore more expensive, making DNA-MVA immunization a less-economic alternative.
The majority of the antigen-specific T cells were CD4 ϩ , although CD8 ϩ cells were also generated. There is strong evidence from animal and human studies that CD4 ϩ T cells are necessary for protective immunity against Mycobacterium infections (3, 4, 19, 27) . However, CD8
ϩ T cells can also be detected following infection and may contribute to protection (24) .
The T-cell responses measured by ELISPOT declined to low levels within 4 months of the MVA booster. However, responses could be boosted to high levels again by a second administration of the MVA, indicating that a population of memory cells had been generated following the initial primingboosting immunization. In a study using a combination of antigens delivered together, macaques immunized by DNA-MVA priming and boosting against simian immunodeficiency virus were protected from development of AIDS symptoms when challenged with a highly pathogenic strain 7 months after the boosting immunization (2), demonstrating the longevity of protective responses generated by this type of immunization.
Responses to each of the immunization regimens varied between animals, as expected in an outbred population. Indeed, it is surprising that responses were generated to such a small antigen (323 amino acids) in almost all animals immunized. The aim of this study was to examine the efficacy of heterologous priming-boosting immunization to induce T-cell responses in cattle, but as strong responses were generated in the majority of cattle using a single small antigen, the protective efficacy of this regimen should be tested using 85A alone. Should this prove partially protective it may be possible to increase protective efficacy by the inclusion of a second antigen in the vaccines. None of the vaccines resulted in systemic or local side effects following immunization. DNA, MVA, and FP9 therefore appear to be both safe and capable of inducing T-cell responses in cattle and should therefore be further evaluated as vaccines against M. bovis infection. The heterologous priming-boosting regimen would also be worth testing as a delivery system for antigens for other cattle diseases in which T-cell responses are believed to be important in mediating protection, including theileriosis, contagious bovine pleuropneumonia, and cowdriosis.
